268 related articles for article (PubMed ID: 26299425)
1. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw.
Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonate and osteonecrosis of the jaw.].
Taguchi A
Clin Calcium; 2017; 27(2):225-231. PubMed ID: 28123124
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in medication-related osteonecrosis of the jaw: a systematic literature review.
Bastida-Lertxundi N; Leizaola-Cardesa IO; Hernando-Vázquez J; Muguerza-Iraola R; Aguilar-Salvatierra A; Gómez-Moreno G; Crettaz JS
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10184-10194. PubMed ID: 31841171
[TBL] [Abstract][Full Text] [Related]
4. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
8. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
9. [Bisphosphonate-associated osteonecrosis of the jaws in lung cancer patients].
Neves I; Morais A; Magalhães A
Rev Port Pneumol; 2013; 19(5):228-32. PubMed ID: 23830508
[TBL] [Abstract][Full Text] [Related]
10. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
11. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of Osteonecrosis of the Jaws.
Aghaloo T; Hazboun R; Tetradis S
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):489-96. PubMed ID: 26412796
[TBL] [Abstract][Full Text] [Related]
13. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.
Balla B; Vaszilko M; Kósa JP; Podani J; Takács I; Tóbiás B; Nagy Z; Lazáry A; Lakatos P
Oral Dis; 2012 Sep; 18(6):580-5. PubMed ID: 22339777
[TBL] [Abstract][Full Text] [Related]
14. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptives and osteonecrosis of the jaw.
Yamashita J; McCauley LK
J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.
Capsoni F; Longhi M; Weinstein R
Arthritis Res Ther; 2006; 8(5):219. PubMed ID: 17049069
[TBL] [Abstract][Full Text] [Related]
17. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.
Fung P; Bedogni G; Bedogni A; Petrie A; Porter S; Campisi G; Bagan J; Fusco V; Saia G; Acham S; Musto P; Petrucci MT; Diz P; Colella G; Mignogna MD; Pentenero M; Arduino P; Lodi G; Maiorana C; Manfredi M; Hallberg P; Wadelius M; Takaoka K; Leung YY; Bonacina R; Schiødt M; Lakatos P; Taylor T; De Riu G; Favini G; Rogers SN; Pirmohamed M; Nicoletti P; ; Fedele S
Oral Dis; 2017 May; 23(4):477-483. PubMed ID: 28039941
[TBL] [Abstract][Full Text] [Related]
18. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
Goodday RH
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
[TBL] [Abstract][Full Text] [Related]
19. Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw.
Kalyan S; Wang J; Quabius ES; Huck J; Wiltfang J; Baines JF; Kabelitz D
J Transl Med; 2015 Jul; 13():212. PubMed ID: 26141514
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
